F-FDG PET/CT-based habitat radiomics combining stacking ensemble learning for predicting prognosis in hepatocellular carcinoma: a multi-center study
- 作者单位
- Affiliations 1 Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. 2 National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. 3 Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. 4 Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China. 5 Department of Molecular Imaging and Nuclear Medicine, Tianjin Cancer Hospital Airport Hospital, Tianjin, 300060, China. 6 Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. wenguixy@yeah.net. 7 National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. wenguixy@yeah.net. 8 Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. xli03@tmu.edu.cn. 9 National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. xli03@tmu.edu.cn.
- 刊名
- BMC cancer
- 年份
- 2024
- 卷号
- Vol.24 No.1
- 页码
- 1457
- ISSN
- 1471-2407
- 摘要
- Background: This study aims to develop habitat radiomic models to predict overall survival for hepatocellular carcinoma , based on the characterization of the intratumoral heterogeneity reflected in F-FDG PET/CT images. Methods: A total of 137 HCC patients from two institutions were retrospectively included. First, intratumoral habitats were achieved by a two-step unsupervised clustering process based on k-means clustering. Second, a total of 4032 radiomic features were extracted based on each ...更多
- 文献类型
- 期刊
- 浏览量
- 11
-
被引次数
-
收录
CPCI-S
PBU_D
Scopus
相同作者单位文献
- [1] Xinhui Lu;Yan Huang;Manchao Liu;Li Xu;Xi Chen;Yinghui Wei;Yihan Zhou;Hang Jin;Fengyu Lu;Yujun Tang;Chengping Wen . Jieduquyuziyin prescription ameliorates systemic lupus erythematosus by targeting MAPK14 to inhibit SAA3-induced macrophage M1 polarization[J] Phytomedicine 2026 . Vol.160 . 158659 .
- [2] Xiubin Jia;Qi Wu;Xiaoyong Zhang;Hequn Lin;Jiahui Gong;Hui Ye;Xueli Hu;Zhaoxia Liang;Danqing Chen;Wei Zhu & …Luyu Ma . Reduced serum acetyl-L-carnitine is associated with hypertensive disorders in women with gestational diabetes mellitus: a multi-omics study[J] Cardiovascular Diabetology
- [3] Guanting Pang, Yaohan Li, Qiwen Shi, Jingkui Tian, Hanmei Lou, Yue Feng . Omics sciences for cervical cancer precision medicine from the perspective of the tumor immune microenvironment[J] Oncology research 2025 . Vol.33 No.4 . 821-836 .
- [4] Guanting Pang, Zhao Wang, Zijian Sun, Xiaojuan Lv, Hui Ye, Liting Shi, Jiahui Ma, Yaohan Li, Zhen Zhang, Jingkui Tian, Hanmei Lou, Wei Zhu, Yue Feng . Integrated Proteomics and Metabolomics Profiling Unveils Biomarkers and Immune Characteristics for Pelvic Lymph Node Metastasis in Cervical Cancer[J] Journal of proteome research 2025 .
- [5] Li Yuan;Sini Li;Yixiang Zhu;Lin Yang;Xue Zhang;Yan Qu;Zhijie Wang;Jianchun Duan;Jia Zhong;Yanhua Tian;Lihui Liu;Boyang Sun;Kailun Fei;Zheng Liu;Jian Zhang;Yan He;Yufeng Guo;DanMing He;Wei Zhuang;Jinsong Zhang . ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201[J] eBioMedicine 2025 . Vol.112 . 105515 .
- [6] Qing Yang MS;Jingyang He MS;Qianyu Zhao MS;Siwei Pan MD;Ruolan Zhang MD;Mengxuan Cao MS;Jiaqing Zhang MS;Weiwei Zhu MS;Mengya Zhou MS;Jintao He MS;Ruixin Xu MS;Can Hu MD;Zaisheng Ye MD;Chen Gao MD;Jie Chai MD;Zhiyuan Xu MD . Tumor location stratifies lymph node metastasis risk and prognosis in gastric cancer: A retrospective analysis of multicenter data and SEER database[J] Surgery 2026 . Vol.194 . 110140 .
- [7] Shijiang Wang, Fen Zhao, Jin Wang, Ying Hua, Yongling Ji, Chaojie Wang, Li Man, Zhiye Zhang, Jun Chen, Jianbing Chen, Hongmei Li, Xuezhen Ma, Zhaohui Liang, Xianyu Meng, Jun Wang, Xiaozhi Zhang, Jinming Yu, Linlin Wang . Prophylactic rhTPO Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiotherapy in Limited-Stage SCLC:A Prospective, Multicenter, Phase II Clinical Trial[J] International journal of radiation oncology, biology, physics 2026 .
- [8] Shanshan Wang, Zhengguang Guo, Boyu Sun, Kai Liu, Jiashuo Chao, Ziyu Xun, Yunchao Wang, Zibo Xu, Ziyue Huang, Hao Wang, Yang Tan, Nan Zhang, Mingjian Piao, Longhao Zhang, Chengjie Li, Shuofeng Li, Jiongyuan Li, Haidan Sun, Feng Qi, Aiwei Wang, XiaoBo Yang, Chengpei Zhu, Hanping Wang, Wei Sun, Haitao Zhao . Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer[J] Gut 2025 .
- [9] Shanshan Wang, Zhengguang Guo, Boyu Sun, Kai Liu, Jiashuo Chao, Ziyu Xun, Yunchao Wang, Zibo Xu, Ziyue Huang, Hao Wang, Yang Tan, Nan Zhang, Mingjian Piao, Longhao Zhang, Chengjie Li, Shuofeng Li, Jiongyuan Li, Haidan Sun, Feng Qi, Aiwei Wang, XiaoBo Yang, Chengpei Zhu, Hanping Wang, Wei Sun, Haitao Zhao . Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer[J] Gut 2026 . Vol.75 No.7 . 1411-1424 .
- [10] Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, Yu-Dong Xiao, Jian-Jian Chen, Xiao-Li Zhu, Yu-Jing Xin, Jin-Zhang Chen, Jun Tie, Kang-Shun Zhu, Lan Zhang, Hai-Bin Shi, Rui-Bao Liu, Ai-Bing Xu, Fanpu Ji, Ming-Sheng Huang, Jian-Song Ji, Chun-Wang Yuan, Wei-Zhu Yang, Guo-Hui Xu, Qiang Tu, Hua Jiang, Hai-Bo Shao, Bao-Qi Shi, Ming Huang, Bin-Yan Zhong, Hai-Dong Zhu, Zheng-Gang Ren, Gao-Jun Teng . Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma[J] Alimentary pharmacology & therapeutics 2026 .